New combo therapy aims to control returning throat cancer
NCT ID NCT07331428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial treatment. First, patients receive a targeted drug (MRG003) plus an immunotherapy (PD-1) for six weeks. Then, they take a chemotherapy pill (capecitabine) with the immunotherapy for up to a year. The goal is to shrink or control the tumor. The study involves 25 adults aged 18-70 with locally recurrent cancer but no spread to other organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCAL RECURRENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers
- Immune boosting duo takes on rare throat cancer